Prevalence of clinical symptoms and their effect on quality of life among patients with benign prostatic hyperplasia at a tertiary health facility in Minna, North central Nigeria
DOI:
https://doi.org/10.51412/psnnjp.2024.18Keywords:
Benign prostate hyperplasia, Quality of life, SF-12, EPIC-CP, Clinical symptomsAbstract
Background: Benign prostate hyperplasia (BPH) is increasingly common among older adult males and its treatment has highly variable effect on patient's quality of life. The persistence of clinical symptoms varies widely and also frequently changes in the course of therapy. The severity of symptoms, side effect(s) of drugs, emotional distress and demographic factors have unpredictable impact on patient's quality of life. Furthermore, the persistence of residual clinical symptoms and abnormally high PSA levels remain an ongoing clinical challenge in the management of the disease. This study therefore aims to assess prevalence and severity of symptoms and quality of life of patients with benign prostate hyperplasia.
Methods: The study was carried out at Ibrahim Badamosi Babangida specialized hospital Minna, Niger State. The hospital's electronic patient's records were used to identify prospective respondents. The medical information of 443 eligible patients were extracted for analysis. The selected patients were followed up during physician appointments and then administered the EPIC-CP and SF-12
questionnaires to determine prevalence and severity of symptoms as well as quality of life respectively. Data was entered into Microsoft excel and scores calculated according to standard procedures. Asubscale score of ≤4 implied absence or mild symptoms, 5 – 8 (moderate symptom) and 9 – 12 severe symptoms (EPIC-CP), while physical and mental components of quality of life score higher than 50 was satisfactory (SF-12).
Results: The mean age of respondents was 65 years and they had been on therapy for 4.9 years. Majority of patients were on Tamulosin monotherapy (63.1%) and Tamulosin / Dutasteride combination therapy (36.9%). The most reported symptoms included sexual dysfunction (96.1%), urinary incontinence (37.6%), urinary obstruction (34.5%) and hormonal symptoms (36%).The quality of life was generally poor and significantly associated with age (p=0.042) and PSA level (p<0.001).There was significant difference in quality of life based on demographic variables (p<0.001).
Conclusion: The persistence of high level of sexual dysfunction and urinary symptoms among patients remains a major medical challenge. Quality of life was generally poor and affected by residual symptoms and side effect of drugs.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Disease Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Diseases in 185 Countries. CA: A Cancer Journal for Clinicians 71 (3): 209 – 249. https://doi:10.3322/caac.21660
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A(2022) Recent global patterns in benign prostate hyperplasia incidence and mortality. Frontiers in Public Health 10: 811044. https://doi.org/10.1016/j.eururo.2019.08.005
Bray F, Laversanne M, Sung H, Ferlay JEM, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74(3): 229 – 263. https://doi.org/10.3322/caac.21834
Emiogun FE, Williams OO, Obafunwa JO (2019) Epidemiology of Benign prostate hyperplasia in Nigeria: Observations at Lagos State University Teaching Hospital. Disease Health Disparities 4: e1-e-9. https://doi:10.9777/chd.2019.1003
Obiora JU (2020)Disease Incidence in Nigeria: A Tertiary Hospital Experience. Asian Pacific Journal of Dis eas e Care 5(1): 27-32. https://doi:10.31557/apjcc.2020.5.1.27-32
Ojewole RW, Oridota ES, Balogun OS, Alabi TO, Ajayi AI, OlajideTA, Tijani KH, Jeje EA, Ogunjimi MA, Ogundare EO (2017) Prevalence of clinical benign prostatic hyperplasia amongst community-dwelling men in a South-Western Nigerian rural setting: A cross-sectional study. African Journal of Urology23(2): 109-115. https://doi.org/10.1016/j.afju.2016.02.004
Nwankwo GA, Asukwu UG, Igwe DU, Ugwuoke AC, Ojide RN, Gbaduo CC (2023) Prevalence of prostate problems among adults in Obio/Akpor Local Government Area (LGA) of Rivers State. Nigerian Journal of Health Promotion 16: 1. https://journals.aphriapub.com/index.php/NJHP/article/view/2334
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A(2018) Global disease statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 diseases in 185 countries. A Cancer Journal for Clinicians 68(6):394- 424. https://doi: 10.3322/caac.21492
Oluwole OP, Rafindadi AH, Shehu MS, Samaila MOA (2015) A ten-year study of benign prostate hyperplasia specimens at Ahmadu Bello University Teaching Hospital (A.B.U.T.H), Zaria, Nigeria. African Journal of Urology 21: 5-18. https://doi:10.1016/j.afju.2014.09.004
Wabinga HR, Nambooze S, Amulen PM, Okello C, Mbus L, Parkin DM (2014) Trends in the incidence of disease in Kampala, Uganda 1991–2010. International Journal of Cancer 135: 432–439. https://doi: 10.1002/ijc.28661
Lorenzoni CF, Ferro J, Carrilho C, Colombet M, Parkin DM (2020) Disease in Mozambique: results from two population based disease registries. International Journal of Cancer 14: 1629–1637. https://doi.org/10.1002/ijc.32953
Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, Amini E, Arabloo J, Argaw AM, Athari SS et al (2022) The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of disease Study 2019. Lancet Healthy Longevity3: e754 – e776. https://doi.org/10.1016/S2666-7568(22)00213-6
Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, Kenfield SA (2017) Benign prostate hyperplasia progression and mortality: a review of diet and lifestyle factors. World Journal of Urology 35: 867 – 874. https://doi:10.1007/s00345-016-1914-3
Reiter-Brennan C, Dzaye O, Al-Mallah MH, Dardari Z, Brawner CA, Lamerato LE, Keteyian SJ, Ehrman JK, Blaha MJ, Visvanathan K et al (2021) Fitness and benign prostate hyperplasia screening, incidence, and mortality: Results from the Henry Ford Exercise Testing (FIT) project. Cancer 127 (11): 1864 – 1870. https://doi:10.1002/cncr.33426
Cam K, Muezzinoglu T, Aydemir O, Buyukalpelli R, Toktas G, Gemalmaz H (2013) Development of a quality of life scale specific for patients with benign prostatic hyperplasia. International Journal of Urology and Nephrology45: 339–346. https://doi:10.1007/s11255-013-0384-4
Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Venkat PS, Fink AK, Naghavi AO, Abrahams A, Mensah JE, Sasu E et al (2018) Contemporary radiation treatment of benign prostate hyperplasia in Africa: a Ghanaian experience. Journal of Global Oncology 4: 1 – 13. https://doi:10.1200/JGO.17.00234
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M Johnson CJ, Estève J et al (2018) Global surveillance of trends in disease survival 2000–2014 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 diseases from 322 population-based registries in 71 countries. Lancet 391: 1023 – 1075. https://doi:10.1016/S0140-6736(17)33326-3
Smits J, Permanyer I (2019) Data descriptor: the subnational human development database. Scientific Data 6: 1 – 15. https//doi.org/10.1038/sdata.2019.38
Nakandi H, Kirabo M, Semugabo C, Kittengo A, Kitayimbwa P, Kalungi S, Maena J (2013) Knowledge, attitudes and practices of Ugandan men regarding benign prostate hyperplasia. African Journal of Urology. 19: 165–170. https://doi:10.1016/j.au.2013.08.001
Baratedi WM, Tshiamo WB, Mogobe KD, McFarland DM (2020) Barriers to benign prostate hyperplasia screening by men in sub-Saharan Africa: an integrated review. Journal of Nursing Scholarship 52: 85 – 94. https://doi:10.1111/jnu.12529
Coughlin SS (2020) A review of social determinants of benign prostate hyperplasia risk, stage, and survival. Prostate International 8: 49–54. https://doi:10.1016/j.prnil.2019.08.001
Singh K, Abdel Goad EH, Ramklass SS (2015) Waiting times for benign prostate hyperplasia diagnosis in KwaZulu-Natal. South African Medical Journal 105: 484. https://doi:10.7196/samj.9192
Meara JG, Leather AJM, Hagander L, Alkire BC, Alonso N, Ameh EA, BicklerSW, Conteh L, Dare AJ, Justine D et al (2015) Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. Lancet 386: 569–624. https://doi:10.1016/j.ijoa.2015.09.006
Zubizarreta E, Van Dyk J, Lievens Y (2017) Analysis of global radiotherapy needs and costs by geographic region and income level. Clinical Oncology 29: 84 – 92. https://doi:10.1016/j.clon.2016.11.011
Krimphove MJ, Cole AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, Sun M, Nabi J, Nguyen PL, Hu JC et al (2019) Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced benign prostate hyperplasia. Prostate Cancer and Prostatic Disease 22: 125–136. https://doi:10.1038/s41391-018-0083-4
DeRouen MC, Schupp CW, Koo J, Yang J, Hertz A, Shariff-Marco S, Cockburn M, Nelson DO, Ingles SA, John EM et al (2018) Impact of individual and neighborhood factors on disparities in benign prostate hyperplasia survival. Cancer Epidemiology 53: 1 – 11. https://doi:10.1016/j.canep.2018.01.003
Memirie ST, Habtemariam MK, Asefa M, Deressa BT, Abayneh G, Tsegaye B, Abraha MM, Ababi G, Jemal A, Rebbeck TR et al (2018) Estimates of disease incidence in Ethiopia in 2015 using population-based registry data. Journal of Global Oncology 4: 1 – 11. https://doi:10.1200/JGO.17.00175
Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Ärnlöv J, Afshin A et al (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 390(10100):1151–1210. https://doi.org/10.1016/S0140-6736(17)32152-9
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Disease incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 136: E 359 – E 386. https://doi:10.1002/ijc.29210
Tucker SR, Speer SA, Peters S (2016) Development of an explanatory model of sexual intimacy following treatment for localized benign prostate hyperplasia: A systematic review and meta-synthesis of qualitative evidence. Social Science Medicine 163: 80 – 88. https://doi:10.1016/j.socscimed.2016.07.001
Gavin AT, Drummond FJ, Donnelly C, O'Leary E, Sharp L, Kinnear HR (2015) Patient-reported 'ever had' and 'current' long-term physical symptoms after benign prostate hyperplasia treatments. British Journal of Urology International 116 (3): 397 – 406. https://doi:10.1111/bju.13036
Baker H, Wellman S, Lavender V 2016) Functional quality-of-life outcomes reported by men treated for localized benign prostate hyperplasia: A systematic literature review. Oncology Nursing Forum 43(2): 199–218. https://doi:10.1188/16.ONF.199-218
Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T et al (2017) Quality of life outcomes after primary treatment for clinically localized benign prostate hyperplasia: a systematic review. European urology 72 (6): 869 – 885. https://doi:10.1016/j.eururo.2017.06.035
Ralph N, Ng SK, Zajdlewicz L, Lepore SJ, Heathcote P, Kneebone A, Dunn JC, Chambers SK (2020) Ten-year quality of life outcomes in men with benign prostate hyperplasia. Psychooncology 29 (2): 444. https://doi:10.1002/pon.5255
Spendelow JS, Joubert HE, Lee H, Fairhurst BR (2018) Coping and adjustment in men with benign prostate hyperplasia: A systematic review of qualitative studies. Journal of Cancer Survivor 12(2): 155–168. https://doi:10.1007/s11764-017-0654-8
Alexis O, Worsley AJ (2018) A meta-synthesis of qualitative studies exploring men's sense of masculinity post–benign prostate hyperplasia treatment. Cancer Nursing 41(4): 298–310. https://doi:10.1097/NCC.0000000000000509
Curtis R, Groarke A, Sullivan F (2014) Stress and self-efficacy predict psychological adjustment at diagnosis of benign prostate hyperplasia. Scientific Reports 4 (1): 1 – 5. https://doi:10.1038/srep05569
Dubey C, De Maria J, Hoeppli C, Betticher DC, Eicher M (2015) Resilience and unmet supportive care needs in patients with disease during early treatment: A descriptive study. European Journal of Oncology Nursing 19(5): 582–588. https://doi:10.1016/j.ejon.2015.03.004
Sharpley CF, Christie DR, Bitsika V, Agnew LL, Andronicos NM, McMillan ME, Richards TM (2017) The use of salivary cortisol as an index of chronic stress that correlates with depression in benign prostate hyperplasia patients. PsychoOncology 26 (9): 1400 – 1402. https://doi:10.1002/pon.4327
Esser P, Mehnert-Theuerkauf A, Friedrich M, Johansen C, Brahler E, Faller H, Härter M, Koch U, Schulz H, Wegscheider K et al (2020) Risk and associated factors of depression and anxiety in men with benign prostate hyperplasia: results from a German multicenter study. PsychoOncology 13: 1–9. https://doi:10.1002/pon.5471
Drummond FJ, Kinnear H, O'Leary E, Gavin A, Sharp L (2015) Long-term health-related quality of life of benign prostate hyperplasia survivors varies by primary treatment. Results from the PiCTure (Benign prostate hyperplasia Treatment, your experience) study. Journal of Cancer Survivor 9 (2): 361 – 372. https://doi:10.1007/s11764-014-0419-6
Chen RC, Basak R, Meyer A-M, Kuo T-M, Carpenter WR, Agans RP, Broughman JR, Reeve BB, Nielsen ME, Usinger DS et al (2017) Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patientreported quality of life among men with localized benign prostate hyperplasia. Journal of American Medical Association 317(11): 1141–1150.
https://doi:10.1001/jama.2017.1652
Donovan JL, Hamdy FC, Lane J, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S et al (2016) Patientreported outcomes after monitoring, surgery, or radiotherapy for benign prostate hyperplasia. New England Journal of Medicine 375(15): 1425 – 1437. https://doi:10.1056/NEJMoa1606221
Tuppin P, Samson S, Fagot-Campagna A, Lukacs B, Alla F, CNAMTS scientific board members et al. Benign prostate hyperplasia outcomes in France: treatments, adverse effects and two-year mortality. BMC Urology 2014; 14: 48. https://doi:10.1186/1471-2490-14-48
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, MartinRM et al (2016)10-year outcomes after monitoring, surgery, or radiotherapy for localized benign prostate hyperplasia. New England Journal of Medicine 375(15): 1415–1424. https://doi:10.1056/NEJMoa1606220
Chambers SK, Ng SK, Baade P, Aitken JF, Hyde MK, Wittert G, Frydenberg M, Dunn J (2017) Trajectories of quality of life, life satisfaction, and psychological adjustment after benign prostate hyperplasia. Psycho-oncology 26(10): 1576–1585. https://doi:10.1002/pon.4342
Kerleau C, Guizard A-V, Daubisse-Marliac L, Heutte N, Mercier M, Grosclaude P, Joly F (2016) Long-term quality of life among localized benign prostate hyperplasia survivors: QALIPRO population-based study. European Journal of Cancer 63: 143 – 153. https://doi:10.1016/j.ejca.2016.05.020
Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL (2017) Long-term quality of life after definitive treatment for benign prostate hyperplasia: patient-reported outcomes in the second post-treatment decade. Cancer Medicine 6(7): 1827–1836. https://doi:10.1002/cam4.1103
Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, Jackson WC, Daignault S, Taylor JMG (2019) Individual and population comparisons of surgery and radiotherapy outcomes in benign prostate hyperplasia using Bayesian multistate models. JAMANetwork Open 2 (2): e 187765. https://doi:10.1001/jamanetworkopen.2018.7765
Halder P, Bhandari Y, Das A, Mamgai A (2020) Association of benign prostatic hyperplasia with multi-morbidity among older adults: Insights from the longitudinal ageing study in India (LASI), First Wave. Cureus 15(12): e50608. https://doi:10.7759/cureus.50608
Zelefsky MJ, Poon BY, Eastham J, Vickers A, Pei X, Scardino PT (2016) Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for benign prostate hyperplasia. Radiotherapy and Oncology 118(1): 85–91. https://doi:10.1016/j.radonc.2015.11.035
Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, Conwill R, McCollum D, Cooperberg MR, GoodmanM et al (2017) Association between radiation therapy, surgery, or observation for localized benign prostate hyperplasia and patient-reported outcomes after 3 years. Journal of American Medical Association 317 (11): 1126 – 1140. https://doi:10.1001/jama.2017.1704
Lavina AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS et al (2019) Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain scores translate to functional outcome? Journal of Urology 2020(6): 1150 – 1158. https://doi.org/10.1097/JU.000000000000392
Ntekim A, Folasire A, Odukoya OA (2023) The prevalence of prostate cancer among young men below 55 years of age in Nigeria. Cancer Control 30: 1 – 7. https://doi:10.1177/10732748231175255
Nakaganda A, Solt K, Kwagonza L, Driscoll D, Kampi R, Orem J (2021) Challenges faced by cancer patients in Uganda: implications for health systems strengthening in resource limited settings. Journal of Cancer Policy 27: 100263. https://doi:10.1016/j.jcpo.2020.100263
Chidebe RCW, Orjiakor CT, Pereira I, Ipiankama SC, Lounsbury DW, Moraes FY (2019) Navigating prostate cancer control in Nigeria. Lancet Oncology 20 (11): 1489 - 1491. https://doi.org/10.1016/S1470-2045(19)30625-4
Okuku F, Orem J, Holoya G, De Boer C, Thompson CL, Cooney MM (2016) Prostate cancer burden at the Uganda cancer institute. Journal of Global Oncology 2(4): 181–185. https://doi:10.1200/JGO.2015.001040
Ekwan R, Bua E, Nantale R, Opito R, Abingwa P, Serwanja Q, Kuteesa J, Mukunya D (2023)Uptake of prostate cancer screening and associated factors among men aged 50 years and above in Lira city, Uganda: a cross-sectional study. BMC Public Health 23: 432. https://doi:10.1186/s12889-023-15348-w
Phua TJ (2021)The etiology and pathophysiology genesis of benign prostatic hyperplasia and prostate cancer: A new perspective. Medicine (Basel) 8(6): 30. https://doi:10.3390/medicines806003
Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW(2020) The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian Journal of Urology 7: 191–202. https://doi:10.1016/j.ajur.2019.10.003
Wang Q, Zhang B, Li B,Yang S, Wang Z,Han C, Wu J, Tian R (2023).Correlation between benign prostatic hyperplasia/lower urinary tract symptoms and renal function in elderly men aged 80 years and older. Clinical Intervention in Aging 18: 61 – 69. https://doi:10.2147/CIA.S392519
Xin C, Fan H, Xie J, Hu J, Sun X, Liu Q (2021) Impact of diabetes mellitus on lower urinary tract symptoms in benign prostatic hyperplasia patients: A meta - analysis. Fronti e r in Endocrinology (Lausanne) 12: 741748. https://doi:10.3389/fendo.2021.741748
Güven EO, Selvi I, Karaismailoğlu E (2019) Association between benign prostate enlargement-related storage and voiding symptoms and systolic blood pressure: a singlecenter cross-sectional study. Sao Paulo Medical Journal 137(5): 446 – 453. https://doi:10.1590/1516-3180.2018.0543. R3.160919
Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, Huang JB, Zeng T (2020) Efficacy and side effects of drugs commonly used for the treatmen of lower urinary tract symptoms associated with benign prostatic hyperplasia. Frontier in Pharmacology 11: 658. https://doi:10.3389/fphar.2020.00658
Bhatt NR, Davis NF, Witjes WP, Bjartell A, Caris C, Patel A, de la TailleA, TubaroA(2021) Quality of life with pharmacological treatment in patients with benign prostatic enlargement: results from the Evolution European Prospective Multicenter Multi-National Registry study. World Journal of Urology 39: 517 – 526. https://doi:10.1007/s00345-020-03219-7
Lee JH, Park YW, Park MH, Yoo TK (2023) Safety and efficacy of Tamulosin 0.4 mg as an initial dose in 1,219 Korean patients with moderate to severe lower urinary tract symptoms: data from a phase IV study. Prostate International 11 (4): 228 - 232. https://doi.org/10.1016/j.prnil.2023.09.003
Lulic Z, Son H, Yoo SB, Cunnington M, Miller D, Cortes V, Park S, Bhak RH, Duh MS (2021) Free combination of Dutasteride plus Tamulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database. BMC Urology 21(1): 178. https://doi:10.1186/s12894-021-00941-1
Song Y, Chen G, Huang P, Hu C, Liu X (2020) Effects of Tamulosin combined with Solifenacin on lower urinary tract symptoms: evidence from a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. Frontiers in Pharmacology 11: 763. https://doi:10.3389/fphar.2020.00763
Dimitripoulos K, Gravas S (2016) Fixed dose combination therapy with Dutasteride and Tamulosin in the management of benign prostatic hyperplasia. Therapeutic Advances in Urology 8 (1): 19 – 28 https://doi:10.1177/1756287215607419
Lee JW, Kim JH (2022) Drug prescription patterns during initial treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: A study based on health insurance review and assessment database. Journal of Korean Medi cal Sc i enc e 37(12): e95. https://doi:10.3346/jkms.2022.37.e95
Abrahams AD, Mensah JE, Tettey Y (2015) Prostate cancer diagnostic methods in Korle Bu Teaching hospital, Accra, Ghana. Postgraduate medical Journal of Ghana 4(2): 51 – 54. https://doi:10.60014/pmjg.v4i2.147
Jo JK, Shinn SH, Kim KS, Moon HS (2021) Changes in prevalence and treatment pattern ofbenign prostatic hyperplasia in Korea. International Neurology Journal 25(4): 347- 354. https://doi:10.5213/inj.2040412.206
Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, Gandhi MC, KaplanSA, Kohler TS, MartinL(2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-Initial Work-up and medical management. Journal of Urology 206 (4): 806 - 817. https://doi:10.1097/JU.0000000000002183
Jiwrajka M, Yaxley W, Ranasinghe S, Perera M, Roberts MJ, Yaxley J (2018) Drugs for benign prostate hypertrophy. Australian Prescriber 41 (5): 150 – 153. https://doi:10.18773/austprescr.2018.045
Albertsen PC (2018) Prostate cancer screening with prostate-specific antigen. Where are we going? Cancer 124 (3): 453 – 455. https://doi.org/10.1002/cncr.31140
Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, Noble S, Lane A, Wolstenholme J (2018) Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels. A case study. Cancer Epidemiology 52: 99 – 105. https://doi:10.1016/j.canep.2017.12.002
Kith G, Lisker S, Sarkar U, Barr-Walker J, Breyer BN, Palmer NR (2021) Defining and measuring adherence in observational studies assessing outcomes of real-world active surveillance for prostate cancer: A systematic review. European Urology and Oncology 4(2): 192-201. https://doi.org/10.1016/j.euo.2019.06.009
Lloyd GL, Marks JM, Ricke WA (2019) Benign prostatic hyperplasia and lower urinary tract symptoms: What is the role and significance of inflammation? Current Urology Report 20(9): 54. https://doi:10.1007/s11934-019-0917-1
Obiatuegwu K, Atim T, Abu S, AisuodionoeShadrach O, Dakum N (2021) Correlation between the severity of erectile dysfunction and prostate size in patients with benign prostatic enlargement. African Journal of Urology 27: 31. https://doi:10.5455/medarh.2016.70.449-452
Asiedu B, Anang Y, Nyarko A, Doku DA, Amoah BY, Santa S, NgalaRA, Asare GA(2017) The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male 20(1): 17–22. https://doi:10.1080/13685538.2016.1272101
Ajayi A, Abraham K (2018) Understanding the role of estrogen in the development of benign prostatic hyperplasia. African Journal of Urology 24(2): 93 – 97. https://doi:10.1007/s11934-015-0534-6
Adejumo B, Williams O, Odigie E, Unachukwu I, Abdulrahman O, Dimkpa U, Uzor S, Adebowale OM, Oke OM (2020) Serum levels of reproductive hormones and their relationship with age in men with benign prostatic hyperplasia in Benin City, Edo State. Health 12(9): 1121 – 1131. https://doi:10.4236/health.2020.129082
Udoh EA, Eyo AE, Ekwere PD (2020)The most bothersome lower urinary tract symptom affecting quality of life using international prostate symptom score in patients with benign prostate hyperplasia. Ibom Medical Journal 13(1): 43 – 49. https://doi.org/10.61386/imj.v13i1.178
Pinto JDO, He H-G, Chan SWC, Wang W (2016) Health-related quality of life and psychological well-being in men with benign prostatic hyperplasia: An integrative review. Japan Journal o f Nursing Science 13 (3): 309 – 323. https://doi:10.1111/jjns.12115
Cai H, Xu Z, Xu T, Yu B, Zou Q (2015) Diabetes mellitus is associated with elevated risk of mortality amongst patients with benign prostate hyperplasia: a meta-analysis of 11 cohort studies. Diabetes and Metabolic Research Review 31: 336–343. https://doi:10.1002/dmrr.2582
Seymour ZA, Daignault-Newton S, McLaughlin PW, Sandler H, Jackson W, Johnson SB, Miller D, Wei J, Sanda M, Hamstra DA (2022) Patient reported outcomes for quality of life (QOL) by expanded prostate cancer index (EPIC) on average 15 years post treatment. Clinical and Translational Radiation Oncology 36: 56–62. https://doi:10.1016/j.ctro.2022.05.007
Bulamu NB, Mpundu-Kaambwa C, O'Callaghan M, Kaambwa B (2022) Responsiveness and construct validity of EPIC-26, A QoL-6d and SF6D following treatment in prostate cancer. BMC Cancer 23: 297. https://doi.org/10.1186/s12885-023-10732-6
Houede N, Rebillard X, Bouvet S, Kabani S, Fabbro-Peray P, Tretarre B, Ménégaux F (2020) Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case control Study. BMC Cancer 20:757. https://doi.org/10.1186/s12885-020-07244-y
Braeckman J, Denis L (2017) Management of BPH then 2000 and now 2016 – From BPH to BPO. Asian Journal of Urology 4(3): 138 – 147. https://doi:10.1016/j.ajur.2017.02.002
Kosilov K, Loparev S, Kuzina I, Kosilova L, Ivanovskaya M, Prokofyeva A (2018) Health related quality of life's dependence on socioeconomic status and demographic characteristics among males with benign prostatichy perplasia. Andrologia 50: 3. https://doi:10.1111/and.12892
Wang M, Jian Z, Gao X, Yuan C, Jin X, Li H, Wang K (2021) Causal associations between educational attainment and 14 urological and reproductive health outcomes: A Mendelian randomization Study. Frontier in Public Health 9: 742952. https://doi: 10.3389/fpubh.2021.742952
Hamid H, Khan IA, Huma S, Khan MN, Khan MI, Salman M, Ali Y, Rahman I (2022) Frequency of cardiovascular problems in patients with benign prostate enlargement. Pakistan Journal of Medical and Health Sciences 16(6): 748 – 750. https://doi.org/10.53350/pjmhs22166748
Park S, Lee K-S, Choi M, Lee M (2022) Factors associated with quality of life in patients with benign prostatic hyperplasia, 2009–2016. Medicine (Baltimore) 101(36): e30091. https://doi:10.1097/MD.0000000000030091
Wang C-k, Zhang JH, Gao Y, Meng X-Y, Zhang H-X, Luo H-H (2024) Quality of life and influencing factors in older adults with benignprostatic hyperplasia. International Journal of Urology Nursing 18 (1): e 12391. https://doi.org/10.1111/ijun.12391
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The Nigerian Journal of Pharmacy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
